Breaking News

Catalent Manufactures Lexicon’s Xermelo Following Approval

To provide commercial supply of first-in-class oral therapy from its Kansas City facility

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lexicon Pharmaceuticals’ orphan drug, Xermelo, has been approved by the U.S. FDA for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Xermelo (telotristat ethyl) 250 mg is a first-in-class orally administered therapy. Catalent Pharma Solutions has been working in partnership with Lexicon since 2007 to develop the drug formulation, and will be manufacturing XERMELO for commercial supply.   “We ar...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters